L74.F WuXi XDC Cayman Inc.

Healthcare Diagnostics & Research Frankfurt Exchange
8.15 EUR
Close of Nov 12, 2026
4.90 9.50
Market cap
EUR 10.3B
P/E
58.2x
P/B
6.92x
ROE
13.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is L74.F undervalued?

Graham number

The Graham number of WuXi XDC Cayman Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

WuXi XDC Cayman Inc. fundamental analysis

No fundamental analysis for WuXi XDC Cayman Inc. yet.

WuXi XDC Cayman Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About WuXi XDC Cayman Inc.

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting service…

Full company profile